AYVAKYT

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Lithuania, Poland, Romania, UK.

Active ingredients

The drug AYVAKYT contains one active pharmaceutical ingredient (API):

1

Avapritinib UNII 513P80B4YJ - AVAPRITINIB

Avapritinib is a tyrosine kinase inhibitor that targets PDGFRA and PDGFRA D842 mutants as well as multiple KIT exon 11, 11/17 and 17 mutants with half maximal inhibitory concentrations (IC50s) less than 25 nM. Certain mutations in PDGFRA and KIT can result in the autophosphorylation and constitutive activation of these receptors which can contribute to tumor cell proliferation. Other potential targets for avapritinib include wild type KIT, PDGFRB, and CSFR1.

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AYVAKYT Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX18		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1828201, 1828212, 1828223, 1878509, 1878510
FR	Base de données publique des médicaments	63189920, 64069767, 65304816
GB	Medicines & Healthcare Products Regulatory Agency	390640, 390643, 390648
LT	Valstybinė vaistų kontrolės tarnyba	1091244, 1091245, 1091246
PL	Rejestru Produktów Leczniczych	100441847, 100441853, 100441860
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69470001, W69471001, W69472001, W69473001, W69474001